Kinloch Capital’s Gilead Sciences GILD Stock Holding History

Kinloch Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-850	Closed	-$50K	–	105
2020 Q4	$50K	Buy	+850	New	+$51.3K	0.04%	103

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kinloch Capital's GILD Position: Q1 2021 in Review

Kinloch Capital sold out of Gilead Sciences (GILD) in Q1 2021, closing a stake of 850 shares — an estimated $50K sold.

Kinloch Capital first reported a position in GILD in Q4 2020 and held it in 1 quarter. The position peaked at $50K in Q4 2020. 1,567 funds tracked by Wall St. Rank hold GILD as of Q1 2021.

Kinloch Capital reported no remaining Gilead Sciences position as of Q1 2021 after selling out during the quarter.
Kinloch Capital sold 850 Gilead Sciences shares in Q1 2021, an estimated $50K.
Kinloch Capital first reported a position in Gilead Sciences in Q4 2020 and held it in 1 quarter.
Kinloch Capital's Gilead Sciences position peaked at $50K in Q4 2020.
1,567 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.

Based on Kinloch Capital's 13F filing for Q1 2021, filed 11 May 2021.